Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Assets (2021 - 2026)

Envoy Medical's Assets history spans 6 years, with the latest figure at $29.8 million for Q1 2026.

  • On a quarterly basis, Assets rose 187.16% to $29.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $29.8 million, a 187.16% increase, with the full-year FY2025 number at $8.6 million, down 25.83% from a year prior.
  • Assets hit $29.8 million in Q1 2026 for Envoy Medical, up from $8.6 million in the prior quarter.
  • Over the last five years, Assets for COCH hit a ceiling of $427.8 million in Q3 2022 and a floor of $2.6 million in Q4 2022.
  • Historically, Assets has averaged $88.7 million across 5 years, with a median of $10.4 million in 2025.
  • Biggest five-year swings in Assets: plummeted 99.4% in 2022 and later surged 223.59% in 2023.
  • Tracing COCH's Assets over 5 years: stood at $2.6 million in 2022, then surged by 223.59% to $8.3 million in 2023, then skyrocketed by 39.5% to $11.5 million in 2024, then decreased by 25.83% to $8.6 million in 2025, then skyrocketed by 248.47% to $29.8 million in 2026.
  • Business Quant data shows Assets for COCH at $29.8 million in Q1 2026, $8.6 million in Q4 2025, and $8.2 million in Q3 2025.